A Phase I/II Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MCS110 in Patients With Prostate Cancer and Bone Metastases.

Trial Profile

A Phase I/II Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MCS110 in Patients With Prostate Cancer and Bone Metastases.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 15 Sep 2015

At a glance

  • Drugs MCS 110 (Primary)
  • Indications Cancer metastases; Prostate cancer
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 04 Sep 2009 Actual patient number (3) added as reported by ClinicalTrials.gov.
    • 04 Sep 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 06 Oct 2008 Planned end date (Sep 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top